Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + low molecular weight hyaluronic acid + aminophenylboronic acid
- Development stage
- Preclinical
- Lead developer
- Shenyang Pharmaceutical University
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Doxorubicin + low molecular weight hyaluronic acid + aminophenylboronic acid (DOX@LR/oHA-APBA) is a pH-responsive, tumor-targeted nanohybrid formulation developed for the treatment of breast cancer. The formulation utilizes laponite RDS (LR) nanodisks as a drug carrier, where doxorubicin is loaded into the interlayer space via ion exchange. The nanodisks are then assembled with a targeted protection layer composed of oligomeric hyaluronic acid (oHA) conjugated to 3-aminophenylboronic acid (APBA). This system targets CD44 receptors overexpressed on cancer cells via the hyaluronic acid moiety, while the boronic acid groups can interact with sialic acid residues on tumor cell membranes. The nanohybrid exhibits acid-dependent, sustained release of doxorubicin in the acidic tumor microenvironment, enhancing cellular uptake and cytotoxicity against breast cancer cells.
- Other names
- DOX@LR/oHA-APBAdoxorubicin-loaded laponite/oligomeric hyaluronic acid-aminophenylboronic acid nanohybrids
02
Targets
CD44 (CD44 antigen)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin + low molecular weight hyaluronic acid + aminophenylboronic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + low molecular weight hyaluronic acid + aminophenylboronic acid.